p53基因的突变常见于人类的癌症包括乳腺癌。p53基因是细胞凋亡的调节因子之一,它的功能性丧失可能会引起细胞凋亡受阻,使癌细胞对化疗产生耐受性。p53突变与淋巴结阳性的乳腺痛的预后有明显的关系,但它与淋巴结阴性乳腺癌的预后关系尚不清楚。为了探讨p53能否预测淋巴结阴性乳腺癌的化疗反应,作者对347例淋巴结阴性乳腺癌(T0-T4)进行了分析。患者均作了包块或乳房切除术,随机分成两组,一组不作化疗,另一组化疗6个疗程(CMF方案),两组均作了局部放疗。平均随访期9.32年(前3年每半年随访一次,以后每年随 Mutations in the p53 gene are common in human cancers including breast cancer. The p53 gene is one of the regulatory factors of apoptosis, and its loss of function may cause the apoptosis to be blocked, so that cancer cells become resistant to chemotherapy. The p53 mutation has a significant relationship with the prognosis of lymph node-positive breast pain, but its relationship with the prognosis of lymph node-negative breast cancer remains unclear. To investigate whether p53 can predict chemotherapy response in lymph node-negative breast cancer, the authors analyzed 347 node-negative breast cancers (T0-T4). All patients underwent mass or mastectomy, were randomly divided into two groups, one group was not treated with chemotherapy, the other group was treated with chemotherapy for 6 cycles (CMF), and both groups were treated with local radiotherapy. The average follow-up period was 9.32 years (the first 3 years were followed up every 6 months, after which